Design Therapeutics Inc.

15.25-1.01-6.21%Vol 1.07M1Y Perf -27.96%
Jun 24th, 2022 16:00 DELAYED
BID11.97 ASK18.98
Open16.65 Previous Close16.26
Pre-Market- After-Market15.25
 - -  - -%
Target Price
25.80 
Analyst Rating
Moderate Buy 2.00
Potential %
69.18 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     61.60
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
38.29 
Earnings Rating
Market Cap850.68M 
Earnings Date
8th Aug 2022
Alpha-0.05 Standard Deviation0.19
Beta2.07 

Today's Price Range

15.0916.65

52W Range

9.6124.34

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
8.08%
1 Month
29.24%
3 Months
-7.80%
6 Months
-16.98%
1 Year
-27.96%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DSGN15.25-1.0100-6.21
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.22-0.24-9.09
Q04 2021-0.22-0.209.09
Q03 2021-0.14-0.21-50.00
Q02 2021-0.18-0.1422.22
Q01 2021-0.06-0.31-416.67
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date8th Aug 2022
Estimated EPS Next Report-0.25
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.07M
Shares Outstanding55.78K
Shares Float28.87M
Trades Count4.72K
Dollar Volume16.49M
Avg. Volume225.98K
Avg. Weekly Volume304.73K
Avg. Monthly Volume200.45K
Avg. Quarterly Volume172.76K

Design Therapeutics Inc. (NASDAQ: DSGN) stock closed at 15.25 per share at the end of the most recent trading day (a -6.21% change compared to the prior day closing price) with a volume of 1.07M shares and market capitalization of 850.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 20 people. Design Therapeutics Inc. CEO is Joao Siffert.

The one-year performance of Design Therapeutics Inc. stock is -27.96%, while year-to-date (YTD) performance is -28.77%. DSGN stock has a five-year performance of %. Its 52-week range is between 9.61 and 24.34, which gives DSGN stock a 52-week price range ratio of 38.29%

Design Therapeutics Inc. currently has a PE ratio of -17.90, a price-to-book (PB) ratio of 2.13, a price-to-sale (PS) ratio of 30 799.90, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -10.95%, a ROC of -11.02% and a ROE of -11.12%. The company’s profit margin is -%, its EBITDA margin is -86 406.10%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Design Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Design Therapeutics Inc.’s next earnings report date is 08th Aug 2022.

The consensus rating of Wall Street analysts for Design Therapeutics Inc. is Moderate Buy (2), with a target price of $25.8, which is +69.18% compared to the current price. The earnings rating for Design Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Design Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Design Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 36.72, ATR14 : 1.31, CCI20 : 122.92, Chaikin Money Flow : 0.06, MACD : 0.66, Money Flow Index : 45.88, ROC : 2.83, RSI : 58.34, STOCH (14,3) : 73.62, STOCH RSI : 0.53, UO : 55.34, Williams %R : -26.38), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Design Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (60.00 %)
2 (50.00 %)
2 (66.67 %)
Moderate Buy
1 (20.00 %)
1 (25.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (20.00 %)
1 (25.00 %)
1 (33.33 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.25
Moderate Buy
2.33

Design Therapeutics Inc.

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.

CEO: Joao Siffert

Telephone: +1 858 293-4900

Address: 6005 Hidden Valley Road, Carlsbad 92011, CA, US

Number of employees: 20

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

52%48%

TipRanks News for DSGN

Fri, 01 Apr 2022 02:37 GMT Design Therapeutics (DSGN) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

Mon, 14 Mar 2022 13:28 GMT Design Therapeutics (DSGN) Gets a Buy Rating from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits